BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1171@pharmaconomics
DTSTAMP:20260707T020054Z
DTSTART;VALUE=DATE:20260324
DTEND;VALUE=DATE:20260325
SUMMARY:GSK Approval — linerixibat
DESCRIPTION:A final FDA approval decision on linerixibat for cholestatic pruritus in primary biliary cholangitis (PBC) is expected Mar 24\, 2026.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1131399/000165495426002008/a8361v.htm\n\nTrack it: https://pharmaconomics.com/e/1171
URL:https://pharmaconomics.com/e/1171
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:GSK catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR